Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients.
Noha Anwar HassunaAya Nabil GamilMahmoud Shokry MahmoudWafaa Khairy MohamedRasha KhairyPublished in: BMC gastroenterology (2022)
To the best of our knowledge, the current study provided the first clinical evidence of the potential use of circulating miRNAs (miR; 122, 155, 196 and 29) as biomarkers of CHC in HCV-4 patients receiving the new DAA regimen (SOF/DAV + RIB), which is a strong motivator for further studies.